Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (211-220 of 337) with videos related to

Pageof 34
Sort By:
Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participantsYunda Huang, Lily Zhang, Amanda Eaton, et al.
Plos Pathogens|March 15, 2021
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection riskErica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, et al.
Viruses|September 28, 2024
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune ResponsesYing Huang, Shomoita Alam, Erica Andersen-Nissen, et al.
Scientific Reports|December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.
The New England Journal of Medicine|June 14, 2018
Effect of Dengue Serostatus on Dengue Vaccine Safety and EfficacySaranya Sridhar, Alexander Luedtke, Edith Langevin, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Virology|November 27, 2009
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesMichael S Seaman, Holly Janes, Natalie Hawkins, et al.
Ebiomedicine|November 14, 2025
Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trialValentin Voillet, Janine van Duijn, Kanika Vanshylla, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Pageof 34

Showing results (211-220 of 337) with videos related to

Sort By:
Pageof 34
Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participantsYunda Huang, Lily Zhang, Amanda Eaton, et al.
Plos Pathogens|March 15, 2021
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection riskErica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, et al.
Viruses|September 28, 2024
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune ResponsesYing Huang, Shomoita Alam, Erica Andersen-Nissen, et al.
Scientific Reports|December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.
The New England Journal of Medicine|June 14, 2018
Effect of Dengue Serostatus on Dengue Vaccine Safety and EfficacySaranya Sridhar, Alexander Luedtke, Edith Langevin, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Virology|November 27, 2009
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesMichael S Seaman, Holly Janes, Natalie Hawkins, et al.
Ebiomedicine|November 14, 2025
Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trialValentin Voillet, Janine van Duijn, Kanika Vanshylla, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Pageof 34